Global Innovative Platforms (GIPL) Cash from Investing Activities (2025 - 2026)
Global Innovative Platforms' (GIPL) quarterly Cash from Investing Activities came in at -$55116.0 in Q2 2026, up 68.59% quarter-over-quarter from -$175448.0 in Q3 2025.
Powered by 
Analysis
Global Innovative Platforms (GIPL) Cash from Investing Activities (2025 - 2026) Analysis & Trends
Global Innovative Platforms has disclosed Cash from Investing Activities across 2 years of filings, most recently posting -$55116.0 for Q2 2026.
- In Q2 2026, Cash from Investing Activities changed N/A year-over-year to -$55116.0; the TTM figure through Jun 2026 stood at -$230564.0 (changed N/A YoY), while the FY2025 annual figure was -$175448.0, changed N/A from the prior year.
- Cash from Investing Activities came in at -$55116.0 for Q2 2026 at Global Innovative Platforms, up from -$175448.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of -$55116.0 in Q2 2026 to a low of -$175448.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Idexx Laboratories | 40.57 Bn | 40.38 Bn | 779.09 Mn | -25.50 Mn |
| 2 | Zoetis | 30.57 Bn | 28.90 Bn | 1.05 Bn | -300.00 Mn |
| 3 | Elanco Animal Health | 11.47 Bn | 10.94 Bn | 798.00 Mn | -110.00 Mn |
| 4 | Phibro Animal Health | 1.43 Bn | 1.35 Bn | 134.40 Mn | -16.45 Mn |
| 5 | Immucell | 87.38 Mn | 78.52 Mn | 2.44 Mn | - |
| 6 | Zhengye Biotechnology Holding | 64.40 Mn | 57.30 Mn | - | - |
| 7 | Global Innovative Platforms | 24.88 Mn | 24.63 Mn | - | -55,116.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -55,116.00 |
| Sep 30, 2025 | -175,448.00 |